Warning letter
Rxhomeo Private Limited: warning letter of Jun 13, 2019
FDA warning letter 575889 · Center for Drug Evaluation and Research
Key facts
| Reference number | 575889 |
|---|---|
| Company | Rxhomeo Private Limited |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Jun 13, 2019 |
| Posted date | Jun 25, 2019 |
| Issuing office | Center for Drug Evaluation and Research |
| Product type | Drugs |
| CFR sections cited | 211.22, 211.34, 211.188, 211.84(d)(1) |
| Inspection city | Hyderabad |
| Inspection start date | Jan 28, 2019 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: